Argenx
ARGX
$952.91
Share price
-0.17%
Change (1 day)
63.16%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Argenx (ARGX) - Total debt
Total debt on the balance sheet as of December 2024 : A$61.47 Million
According to Argenx 's latest financial reports the company's total debt is A$61.47 Million. A company’s total debt is the sum of all current and non-current debts.
Argenx - Total debt on balance sheet (from 2017 to 2020)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | A$62.78 M | 113.88% |
| 2023-12-31 | A$29.35 M | 60.76% |
| 2022-12-31 | A$18.26 M | 15.47% |
| 2021-12-31 | A$15.81 M | 2.37% |
| 2020-12-31 | A$15.44 M | 31.91% |
| 2019-12-31 | A$11.71 M | |
| 2018-12-31 | N/A | |
| 2017-12-31 | N/A | |
| 2013-12-31 | N/A | -100% |
| 2012-12-31 | A$2.84 M | 2.55% |
| 2011-12-31 | A$2.77 M |